FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

708 letters match. Newest first.

  1. Yangzhou H&R Plastic Daily Chemical Co., Ltd.

    Yangzhou H&R Plastic Daily Chemical, a Chinese contract manufacturer, lacked release testing and CGMP controls for its OTC drug.

    High risk
  2. 4U Health

    FDA says 4U Health sells an unapproved HIV dried blood spot self-collection kit, making it adulterated and misbranded.

    High risk
  3. IsoTis OrthoBiologics, Inc.

    IsoTis OrthoBiologics in Irvine, CA failed to properly fix and assess possible particulate contamination in its Accell bone filler devices, FDA says.

    High risk
  4. Patcos Cosmetics Pvt. Ltd.

    Patcos Cosmetics, an Indian OTC drug manufacturer, was cited for insanitary conditions and CGMP violations after a 2025 FDA inspection.

    High risk
  5. OraLabs, Inc.

    FDA warned OraLabs, an OTC drugmaker in Parker, Colorado, that it skipped microbial release testing and dismissed contamination findings.

    High risk
  6. Flowchem Pharma Private Limited

    FDA warned India's Flowchem Pharma over dirty API equipment, exposed materials and untested impurities, and blocked its drug imports.

    High risk
  7. Vedic Lifesciences Pvt. Ltd.

    FDA warns Vedic Lifesciences over false final reports for three nonclinical drug studies.

    Medium
  8. Tentamus India Private Limited

    FDA warned India-based contract testing lab Tentamus over destroyed and backdated lab records and limited inspection access.

    High risk
  9. Fareva Morton Grove

    FDA found microbial contamination risks and data integrity failures at Fareva Morton Grove's OTC drug manufacturing.

    High risk
  10. Raw Bistro Inc.

    FDA warns Raw Bistro that its raw dog food contained Salmonella Paratyphi and its pathogen controls were inadequate.

    High risk
  11. Exactech, Inc. dba Advita Ortho

    FDA warned Exactech/Advita Ortho over quality-system failures in Equinoxe shoulder implants found during a July 2025 Sarasota inspection.

    High risk
  12. Diasol, Inc.

    Diasol sold unapproved citric acid hemodialysis disinfectants and had quality system violations, FDA says.

    High risk
  13. Yuyao City Boss Vegetable Factory Co. Ltd.

    Yuyao City Boss Vegetable Factory failed to keep or fabricated processing records for U.S.-shipped acidified mustard stems.

    High risk
  14. A. Nelson & Co. Ltd.

    London homeopathic drug maker A. Nelson & Co. shipped children's products without microbial testing and discarded quality records.

    High risk
  15. AQ USA Inc., d.b.a Ross Healthcare Inc.

    FDA warns AQ USA/Ross Healthcare over current good manufacturing practice violations in drugs, including missing microbial testing and inadequate component and stability controls.

    High risk
  16. Cosmetic Manufacturers Pty Ltd.

    FDA warned Cosmetic Manufacturers Pty Ltd. that its Australian drug site was adulterated due to CGMP violations and placed its drugs on import alert.

    High risk
  17. ProDx Health

    FDA warns ProDx Health that its HIV sample self-collection kits are sold without marketing authorization.

    High risk
  18. Bio-Medical Pharmaceutical Manufacturing Corporation

    Bio-Medical Pharmaceutical Manufacturing, a Houston contract manufacturer, was cited for sterile OTC drug current good manufacturing practice (CGMP) failures and drug listing violations.

    High risk
  19. Central Coast Multispecialty Medical Group, Inc.

    FDA warns Central Coast Multispecialty Medical Group over incomplete donor screening and eligibility for reproductive tissue.

    High risk
  20. Conceive Fertility Center

    FDA says Conceive Fertility Center in Dallas used incomplete donor screening and testing for reproductive cells.

    High risk
  21. Louisville Reproductive Center

    Louisville Reproductive Center failed to properly test and screen semen donors for infectious diseases, FDA found.

    High risk
  22. Signature Formulations, LLC

    FDA says Signature Formulations made OTC drugs on shared equipment without adequate controls, risking hormone contamination.

    High risk
  23. Boothwyn Pharmacy, LLC

    Boothwyn Pharmacy made sterile drugs in insanitary conditions and shipped lots that failed sterility and potency tests.

    High risk
  24. HTO Nevada, Inc. dba Kirkman

    HTO Nevada dba Kirkman, an OTC drug contract manufacturer, was cited for CGMP violations including mislabeled reformulated drugs.

    High risk
  25. Flextronics America LLC

    FDA warns Flextronics America, contract maker of FreeStyle Libre 3 glucose sensors in Austin, TX, over an unvalidated assembly step and weak corrective actions.

    High risk
  26. Abbott Diabetes Care, Inc.

    FDA warns Abbott Diabetes Care that FreeStyle Libre 3 glucose monitors lacked design transfer and finished-device accuracy release testing.

    High risk
  27. CC Pollen Company

    FDA warns CC Pollen Company of Glendale, Arizona, that its bee pollen and royal jelly supplements are adulterated and misbranded.

    High risk
  28. Fulijaya Manufacturing SDN. BHD.

    Fulijaya Manufacturing in Malaysia failed CGMP (drug manufacturing rules) for OTC drugs, with missing lab data, flawed microbial tests, and weak stability data.

    High risk
  29. Meridian Bioscience, Inc

    FDA warns Meridian Bioscience's Magellan Diagnostics over quality system failures and unreported problems with its blood lead test kits.

    High risk
  30. MAST Biosurgery USA, Inc.

    MAST Biosurgery USA never ran promised endotoxin tests on its SurgiWrap FROST surgical mesh and failed to report patient injuries, FDA says.

    High risk
  31. Germaphobix

    FDA warns Germaphobix that its unapproved HIV dried blood spot self-collection kit is adulterated and misbranded.

    High risk
  32. Genetrace

    FDA warned Genetrace that its HIV dried blood spot self-collection kit is unapproved and misbranded.

    High risk
  33. Genovate

    FDA warns Genovate over selling an unapproved HIV dried-blood-spot self-collection kit without marketing authorization.

    High risk
  34. Integrity Partners Group

    FDA warns Integrity Partners Group about manufacturing failures at its Chemisphere drug plant, including inadequate testing, supplier verification, cleaning, and process validation.

    High risk
  35. LXR Biotech, LLC

    FDA warns LXR Biotech over CGMP (manufacturing quality rules) failures for Eternal Energy supplements, making them adulterated (legally unfit as made).

    Medium
  36. Chemspec Chemicals Private Limited

    FDA warns Indian API maker Chemspec Chemicals over missing batch records and data integrity failures.

    High risk
  37. ASP Global, LLC. dba Anatomy Supply Partners, LLC.

    FDA cites ASP Global for quality-system, reporting, and unapproved-change violations involving Safe-T-Fill blood collection devices.

    High risk
  38. Absolutely Natural

    FDA warned Absolutely Natural of Melbourne, Florida, over nonprescription drug manufacturing violations, including weak contamination investigations and component testing.

    High risk
  39. Tower Laboratories Ltd.

    FDA warned Tower Laboratories, an OTC drug maker in Montague, MI, for weak out-of-specification investigations and unproven test methods.

    High risk
  40. LiquidCapsule Manufacturing, LLC

    LiquidCapsule Manufacturing failed CGMP (current good manufacturing practice) for OTC drugs, including component identity testing and process validation failures.

    High risk
  41. Unipack LLC

    FDA says Unipack LLC released suppositories without adequate out-of-specification investigations, complete lab records, and required USP testing.

    High risk
  42. Palamur Biosciences Private Limited

    FDA warns Palamur Biosciences over GLP violations in medical device safety testing and inadequate corrective actions.

    High risk
  43. Guangdong Renhe Guozhuang Biotechnology Co., Ltd.

    FDA warns Guangdong Renhe Guozhuang Biotechnology over CGMP failures in OTC drug manufacturing.

    High risk
  44. Medinatura New Mexico, Inc.

    FDA cited Medinatura New Mexico for drug manufacturing rule violations, including weak component testing and cleaning.

    High risk
  45. SV Labs Corporation

    SV Labs released microbe-contaminated OTC drug products and lacked water, process and quality controls, FDA says.

    High risk
  46. Darmerica, LLC

    FDA warns Darmerica over manufacturing-quality violations and mislabeled drug ingredients, including retatrutide.

    High risk
  47. King Farm

    King Farm's horse feed held fumonisin up to 36.1 ppm; FDA ties it to at least 30 horse deaths.

    High risk
  48. Sklar Personal Care Inc.

    Sklar Personal Care’s drug facility failed CGMP (current good manufacturing practice), including untested raw materials and inadequate cleaning, process validation, and quality oversight.

    High risk
  49. 3D Imaging Drug Design and Development LLC

    FDA warns 3D Imaging of CGMP failures in sterile PET drug manufacturing and outdated drug listings.

    High risk
  50. Green Valley Fertility Partners

    FDA cited Green Valley Fertility Partners for donor eligibility failures involving oocyte HCT/Ps, including missing communicable disease testing and screening.

    High risk